Celltrion Executive and Leadership Team

Younghwan Kim, the Division Chief Financial Officer at Celltrion, manages the company's financial health and strategic fiscal planning. Younghwan Kim oversees all financial operations, including budgeting, forecasting, and investment analysis, crucial for Celltrion's research, development, and manufacturing endeavors. This role involves ensuring robust financial controls and driving fiscal discipline to support the expansion of biosimilar and innovative drug production. By analyzing market trends and economic factors, the Division Chief Financial Officer guides investment decisions to maximize shareholder value and sustain long-term growth. Younghwan Kim's financial acumen is vital for securing funding and managing resources effectively, enabling Celltrion to pursue its mission of making advanced therapeutics more accessible. The financial strategies implemented by Younghwan Kim directly contribute to the company's ability to bring affordable biosimilar mAbs to patients worldwide.

Lee Seung Joon, the President at Celltrion, provides overarching strategic direction and executive leadership for the company's global operations. Lee Seung Joon guides the organization's vision, focusing on advancing Celltrion's position as a leader in biosimilar and innovative drug development. This critical role involves fostering a culture of innovation and operational excellence across all departments, from research and manufacturing to marketing and sales. By setting ambitious goals and ensuring strategic alignment, Lee Seung Joon drives the company's mission to enhance patient access to affordable, high-quality therapeutics. The President's leadership is instrumental in navigating complex regulatory landscapes and expanding market reach for Celltrion's groundbreaking products. Lee Seung Joon's commitment to scientific advancement and patient welfare underpins the company's sustained growth and impact in the biopharmaceutical industry.

Youngsup Han, the President, Celltrion (China), spearheads Celltrion's strategic initiatives and operational management within the vital Chinese market. Youngsup Han directs the expansion and market penetration of Celltrion's biosimilar and innovative drug portfolio across China, ensuring compliance with local regulations and market dynamics. This leadership role is crucial for increasing patient access to advanced therapeutics in one of the world's largest healthcare markets. By fostering strong relationships with local stakeholders and healthcare providers, Youngsup Han drives the adoption of Celltrion's high-quality, affordable treatments. The focus remains on building a robust commercial infrastructure and executing effective market strategies to meet the growing demand for biosimilar mAbs. Youngsup Han's leadership is key to realizing Celltrion's global mission within the significant Chinese territory.

Jiyun Seol, the Head Chief Marketing Officer, Operations Department at Celltrion, directs global marketing strategies and operational execution. Overseeing the deployment of Celltrion's biosimilar and innovative drug portfolios, Jiyun Seol ensures alignment with market demands and patient access initiatives. This leadership involves managing cross-functional teams to enhance product visibility and market penetration across key regions. By optimizing operational workflows, Jiyun Seol drives efficiency in bringing advanced therapeutics to a wider patient base. The focus remains on expanding Celltrion's reach and impact through strategic marketing campaigns and robust operational support, reinforcing the company's mission to provide affordable biosimilar mAbs. Jiyun Seol's oversight extends to market analysis and competitive positioning, ensuring Celltrion maintains its leadership in the biopharmaceutical sector.

Dong Kim, the Chief Marketing Officer, Quality Assurance at Celltrion, bridges the critical functions of product quality and market strategy. Dong Kim ensures that marketing initiatives accurately reflect the high standards of Celltrion's biosimilar and innovative drug development, maintaining trust and credibility with healthcare professionals and patients. This dual focus involves close collaboration with research and development teams to translate quality metrics into compelling market narratives. By championing quality assurance in all marketing communications, Dong Kim reinforces Celltrion's commitment to delivering safe and effective therapeutics. The strategic direction provided by Dong Kim supports the company's objective of expanding access to advanced treatments. This leadership ensures that Celltrion's market presence is built on a foundation of unwavering quality and scientific integrity, driving forward the mission to provide affordable biosimilar mAbs.

Juby Jacob-Nara, the Senior Vice President and Chief Medical Officer at Celltrion, leads the company's medical affairs and clinical development strategies. Juby Jacob-Nara oversees the scientific evaluation and clinical validation of Celltrion's biosimilar and innovative drug pipeline, ensuring adherence to the highest medical and ethical standards. This role is pivotal in translating scientific research into tangible patient benefits, driving the development of advanced therapeutics. By guiding clinical trials and medical communication, Juby Jacob-Nara ensures that Celltrion's products meet critical medical needs and regulatory requirements. The strategic medical insights provided by Juby Jacob-Nara are essential for expanding patient access to affordable biosimilar mAbs. This leadership ensures Celltrion's commitment to improving global health outcomes through evidence-based medicine and innovative drug solutions.